A Phase 1 interventional study of tamsulosin (Astellas) and Tamsulosin HCL in Prostatic Hyperplasia, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-04-17.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies testing tamsulosin in Prostatic Hyperplasia — 8 open to participants now, 8 under way, 1 of them phase 3. Tamsulosin · Prostatic Hyperplasia.
Among the 48 studies testing tamsulosin in Prostatic Hyperplasia, this one is the 42nd largest by enrollment, is one of 5 that started in 2015, is one of 9 in phase 1, and was the 25th registered.
828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.
Browse Prostatic Hyperplasia studies →8 of the 48 studies testing tamsulosin in Prostatic Hyperplasia are open now, in 3 countries. Recruiting first, the newest first:
Ain Shams University · Sites in Egypt
Ages 45+
Beni-Suef University · Sites in Egypt
Ages 50+ · Men only
Ankara Training and Research Hospital · Sites in Turkey
Ages 40–85 · Men only
Azienda Ospedaliero Universitaria Maggiore della Carita · Sites in Italy
Ages 40+ · Men only · Healthy volunteers
Il-Yang Pharm. Co., Ltd.
Ages 45+ · Men only
By country, each count listing its studies:
Tamsulosin: first FDA approval 1997 (FLOMAX). What it is approved for, and how studies give it, is on its page →
Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 64 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 5 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 92 across 627 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 118 across the 48 interventional studies. Of the 35 that completed or were terminated, 12 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 48 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
18 studies in Prostatic Hyperplasia by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 18 finished, 3 (17%) have results posted.
Among the 18 studies in Prostatic Hyperplasia by Boehringer Ingelheim, this one is one of 2 that started in 2015, is one of 2 in phase 1, and was the 16th registered.
Boehringer Ingelheim’s Prostatic Hyperplasia studies by the year they started, since 1998.
5 of the studies testing tamsulosin in Prostatic Hyperplasia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07870759Phase 3Il-Yang Pharm. Co., Ltd.Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia | 2027-08-31 |
| NCT07722884Ain Shams UniversityTamsulosin Monotherapy Versus Combination Therapy With Tadalafil (2.5 mg vs 5 mg) in Managing Male LUTS Secondary to BPH | 2027-01-01 |
| NCT07743034Mohsen PouraziziIris Structural Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients | 2027-04 |
| NCT07743060Mohsen PouraziziPupil Size and Choroidal Thickness Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients | 2027-04 |
| NCT07650968Beni-Suef UniversityTamsulosin Dose Escalation or Silodosin Switch Before Trial Without Catheter in BPH-Related Acute Urinary Retention | 2027-05 |
Add all 5 to your calendar (.ics) → With an account.
Among the 48 studies testing tamsulosin in Prostatic Hyperplasia, from their registry updates:
Among Boehringer Ingelheim’s 18 in Prostatic Hyperplasia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Two tamsulosin HClformulations will be tested in fed state
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Health male volunteers 18 years and older
Exclusion criteria:
History of or allergy to IMP or its or any related medication
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tamsulosin HCL
Drug: tamsulosin (Astellas)
Maximum Measured Concentration (Cmax)
Maximum measured concentration of analyte in plasma (Cmax)
Time frame: Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
Area Under the Concentration-time Curve From 0 to the Time of the Last Quantifiable Concentration (AUC0-tz)
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz)
Time frame: Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
Area Under the Concentration-time Curve From 0 Extrapolated to Infinity (AUC0-inf)
Area under the concentration-time curve of analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf).
Time frame: Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
Time to Maximum Plasma Concentration (Tmax)
Time from last dosing to the maximum plasma concentration (tmax).
Time frame: Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
Terminal Elimination Rate Constant (λz)
Terminal elimination rate constant in plasma (λz)
Time frame: Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
Apparent Terminal Elimination Half-life (t1/2)
Apparent terminal elimination half-life of the analyte in plasma (t1/2)
Time frame: Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
| Milestone | Tamsulosin HCl (Test) / Flomax Relief (Reference) | Flomax Relief (Reference) / Tamsulosin HCl (Test) |
|---|---|---|
| Started | 17 | 17 |
| Completed | 17 | 17 |
| Not completed | 0 | 0 |
Maximum measured concentration of analyte in plasma (Cmax)
| pg/mL | Tamsulosin HCl (Test) | Flomax Relief (Reference) |
|---|---|---|
| Maximum Measured Concentration (Cmax) | 8826 ± 31.8 | 8856 ± 34.0 |
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz)
| h*pg/mL | Tamsulosin HCl (Test) | Flomax Relief (Reference) |
|---|---|---|
| Area Under the Concentration-time Curve From 0 to the Time of the Last Quantifiable Concentration (AUC0-tz) | 164700 ± 42.4 | 165400 ± 43.7 |
Area under the concentration-time curve of analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf).
| h*pg/mL | Tamsulosin HCl (Test) | Flomax Relief (Reference) |
|---|---|---|
| Area Under the Concentration-time Curve From 0 Extrapolated to Infinity (AUC0-inf) | 170100 ± 44.1 | 171000 ± 45.2 |
Time from last dosing to the maximum plasma concentration (tmax).
| Hours | Tamsulosin HCl (Test) | Flomax Relief (Reference) |
|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) | 7.51 (4.00 to 12.01) | 8.00 (4.00 to 24.01) |
Terminal elimination rate constant in plasma (λz)
| 1/hour | Tamsulosin HCl (Test) | Flomax Relief (Reference) |
|---|---|---|
| Terminal Elimination Rate Constant (λz) | 0.05 ± 21.6 | 0.05 ± 21.9 |
Apparent terminal elimination half-life of the analyte in plasma (t1/2)
| hours | Tamsulosin HCl (Test) | Flomax Relief (Reference) |
|---|---|---|
| Apparent Terminal Elimination Half-life (t1/2) | 13.16 ± 21.6 | 13.21 ± 21.9 |
Collected over Up to 72 hours. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tamsulosin HCl (Test) | — | 0/34 (0%) | 5/34 (14.7%) |
| Flomax Relief (Reference) | — | 0/34 (0%) | 1/34 (2.9%) |
| Event | Tamsulosin HCl (Test) | Flomax Relief (Reference) |
|---|---|---|
| HeadacheNervous system disorders | 5/34 | 1/34 |
Treated set which included all subjects who received at least one dose of investigational medicinal product.
| Age, Continuous(Years) | All Subjects |
|---|---|
| Mean | 24.6 ± 5.53 |
| Sex: Female, Male(Participants) | All Subjects |
|---|---|
| Female | 0 |
| Male | 34 |
No study locations are listed for this record.
The record gives a start of Apr 2015, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2020, 4 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tamsulosin